25 XP   0   0   10

Cyclopharm Ltd
Buy, Hold or Sell?

Let's analyse Cyclopharm together

PenkeI guess you are interested in Cyclopharm Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyclopharm Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyclopharm Ltd

I send you an email if I find something interesting about Cyclopharm Ltd.

Quick analysis of Cyclopharm (30 sec.)










What can you expect buying and holding a share of Cyclopharm? (30 sec.)

How much money do you get?

How much money do you get?
A$0.02
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
A$0.39
Expected worth in 1 year
A$0.11
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$-0.24
Return On Investment
-13.1%

For what price can you sell your share?

Current Price per Share
A$1.83
Expected price per share
A$1.5762 - A$1.85
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Cyclopharm (5 min.)




Live pricePrice per Share (EOD)

A$1.83

Intrinsic Value Per Share

A$-1.33 - A$-0.49

Total Value Per Share

A$-0.94 - A$-0.10

2. Growth of Cyclopharm (5 min.)




Is Cyclopharm growing?

Current yearPrevious yearGrowGrow %
How rich?$23.8m$28.1m-$4.2m-17.9%

How much money is Cyclopharm making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$3.2m-$1m-23.8%
Net Profit Margin-28.5%-28.5%--

How much money comes from the company's main activities?

3. Financial Health of Cyclopharm (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Cyclopharm? (5 min.)

Welcome investor! Cyclopharm's management wants to use your money to grow the business. In return you get a share of Cyclopharm.

What can you expect buying and holding a share of Cyclopharm?

First you should know what it really means to hold a share of Cyclopharm. And how you can make/lose money.

Speculation

The Price per Share of Cyclopharm is A$1.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyclopharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyclopharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.39. Based on the TTM, the Book Value Change Per Share is A$-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyclopharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.05-2.5%-0.05-2.5%-0.04-1.9%-0.03-1.6%-0.02-0.9%
Usd Book Value Change Per Share-0.05-2.5%-0.05-2.5%0.189.9%0.031.5%0.020.9%
Usd Dividend Per Share0.010.3%0.010.3%0.010.3%0.010.3%0.000.2%
Usd Total Gains Per Share-0.04-2.1%-0.04-2.1%0.1910.2%0.031.8%0.021.2%
Usd Price Per Share0.77-0.77-1.07-0.99-0.69-
Price to Earnings Ratio-16.62--16.62--30.55--610.07--299.97-
Price-to-Total Gains Ratio-19.45--19.45-5.74-41.33--76.54-
Price to Book Ratio3.01-3.01-3.58-6.23-5.37-
Price-to-Total Gains Ratio-19.45--19.45-5.74-41.33--76.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.19682
Number of shares835
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share-0.050.03
Usd Total Gains Per Share-0.040.03
Gains per Quarter (835 shares)-32.8526.89
Gains per Year (835 shares)-131.40107.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
121-152-141189098
241-304-27236179206
362-456-40353269314
482-608-53471359422
5103-760-66589449530
6123-912-796107538638
7144-1064-927125628746
8164-1215-1058142718854
9185-1367-1189160808962
10205-1519-13201788971070

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%3.07.00.030.0%9.09.00.050.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%10.08.00.055.6%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.08.055.6%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%6.04.00.060.0%11.07.00.061.1%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Cyclopharm

About Cyclopharm Ltd

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Fundamental data was last updated by Penke on 2024-02-04 22:56:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Cyclopharm Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyclopharm earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cyclopharm to the Medical Devices industry mean.
  • A Net Profit Margin of -28.5% means that $-0.28 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyclopharm Ltd:

  • The MRQ is -28.5%. The company is making a huge loss. -2
  • The TTM is -28.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-28.5%TTM-28.5%0.0%
TTM-28.5%YOY-28.5%0.0%
TTM-28.5%5Y-23.8%-4.7%
5Y-23.8%10Y-13.4%-10.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.5%-11.2%-17.3%
TTM-28.5%-16.7%-11.8%
YOY-28.5%-13.6%-14.9%
5Y-23.8%-19.1%-4.7%
10Y-13.4%-22.6%+9.2%
1.1.2. Return on Assets

Shows how efficient Cyclopharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyclopharm to the Medical Devices industry mean.
  • -13.3% Return on Assets means that Cyclopharm generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyclopharm Ltd:

  • The MRQ is -13.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.3%TTM-13.3%0.0%
TTM-13.3%YOY-9.0%-4.3%
TTM-13.3%5Y-10.6%-2.8%
5Y-10.6%10Y-6.9%-3.7%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.3%-3.5%-9.8%
TTM-13.3%-4.4%-8.9%
YOY-9.0%-3.6%-5.4%
5Y-10.6%-3.9%-6.7%
10Y-6.9%-4.3%-2.6%
1.1.3. Return on Equity

Shows how efficient Cyclopharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyclopharm to the Medical Devices industry mean.
  • -18.1% Return on Equity means Cyclopharm generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyclopharm Ltd:

  • The MRQ is -18.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.1%TTM-18.1%0.0%
TTM-18.1%YOY-11.7%-6.4%
TTM-18.1%5Y-15.6%-2.5%
5Y-15.6%10Y-13.8%-1.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.1%-3.8%-14.3%
TTM-18.1%-5.0%-13.1%
YOY-11.7%-4.5%-7.2%
5Y-15.6%-5.5%-10.1%
10Y-13.8%-6.2%-7.6%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Cyclopharm Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyclopharm is operating .

  • Measures how much profit Cyclopharm makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyclopharm to the Medical Devices industry mean.
  • An Operating Margin of -25.7% means the company generated $-0.26  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyclopharm Ltd:

  • The MRQ is -25.7%. The company is operating very inefficient. -2
  • The TTM is -25.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-25.7%TTM-25.7%0.0%
TTM-25.7%YOY-24.5%-1.2%
TTM-25.7%5Y-21.1%-4.5%
5Y-21.1%10Y-10.8%-10.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.7%-31.8%+6.1%
TTM-25.7%-14.7%-11.0%
YOY-24.5%-12.3%-12.2%
5Y-21.1%-20.5%-0.6%
10Y-10.8%-25.1%+14.3%
1.2.2. Operating Ratio

Measures how efficient Cyclopharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.33 means that the operating costs are $1.33 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cyclopharm Ltd:

  • The MRQ is 1.329. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.329. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.329TTM1.3290.000
TTM1.329YOY1.393-0.064
TTM1.3295Y1.390-0.061
5Y1.39010Y1.177+0.213
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3291.454-0.125
TTM1.3291.478-0.149
YOY1.3931.450-0.057
5Y1.3901.484-0.094
10Y1.1771.380-0.203
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Cyclopharm Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyclopharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 4.65 means the company has $4.65 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyclopharm Ltd:

  • The MRQ is 4.646. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.646. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.646TTM4.6460.000
TTM4.646YOY5.831-1.184
TTM4.6465Y4.377+0.269
5Y4.37710Y3.648+0.729
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6462.883+1.763
TTM4.6462.860+1.786
YOY5.8313.719+2.112
5Y4.3773.643+0.734
10Y3.6483.554+0.094
1.3.2. Quick Ratio

Measures if Cyclopharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyclopharm to the Medical Devices industry mean.
  • A Quick Ratio of 3.53 means the company can pay off $3.53 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyclopharm Ltd:

  • The MRQ is 3.529. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.529. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.529TTM3.5290.000
TTM3.529YOY5.027-1.498
TTM3.5295Y3.508+0.021
5Y3.50810Y2.891+0.617
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5291.627+1.902
TTM3.5291.634+1.895
YOY5.0272.201+2.826
5Y3.5082.268+1.240
10Y2.8912.263+0.628
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Cyclopharm Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyclopharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyclopharm to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.26 means that Cyclopharm assets are financed with 26.3% credit (debt) and the remaining percentage (100% - 26.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyclopharm Ltd:

  • The MRQ is 0.263. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.263. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.263TTM0.2630.000
TTM0.263YOY0.227+0.035
TTM0.2635Y0.290-0.027
5Y0.29010Y0.2900.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2630.382-0.119
TTM0.2630.385-0.122
YOY0.2270.329-0.102
5Y0.2900.442-0.152
10Y0.2900.465-0.175
1.4.2. Debt to Equity Ratio

Measures if Cyclopharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyclopharm to the Medical Devices industry mean.
  • A Debt to Equity ratio of 35.6% means that company has $0.36 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyclopharm Ltd:

  • The MRQ is 0.356. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.356. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.356TTM0.3560.000
TTM0.356YOY0.294+0.062
TTM0.3565Y0.417-0.061
5Y0.41710Y0.425-0.008
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3560.546-0.190
TTM0.3560.548-0.192
YOY0.2940.465-0.171
5Y0.4170.620-0.203
10Y0.4250.699-0.274
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Cyclopharm Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cyclopharm generates.

  • Above 15 is considered overpriced but always compare Cyclopharm to the Medical Devices industry mean.
  • A PE ratio of -16.62 means the investor is paying $-16.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyclopharm Ltd:

  • The EOD is -25.990. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.616. Based on the earnings, the company is expensive. -2
  • The TTM is -16.616. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-25.990MRQ-16.616-9.373
MRQ-16.616TTM-16.6160.000
TTM-16.616YOY-30.553+13.936
TTM-16.6165Y-610.073+593.457
5Y-610.07310Y-299.967-310.107
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-25.990-1.201-24.789
MRQ-16.616-1.609-15.007
TTM-16.616-2.182-14.434
YOY-30.553-2.571-27.982
5Y-610.073-2.051-608.022
10Y-299.967-1.851-298.116
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyclopharm Ltd:

  • The EOD is -23.771. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.198. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.198. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-23.771MRQ-15.198-8.573
MRQ-15.198TTM-15.1980.000
TTM-15.198YOY-55.185+39.987
TTM-15.1985Y-52.790+37.592
5Y-52.79010Y28.343-81.133
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-23.771-1.924-21.847
MRQ-15.198-2.404-12.794
TTM-15.198-3.958-11.240
YOY-55.185-6.019-49.166
5Y-52.790-5.249-47.541
10Y28.343-5.844+34.187
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyclopharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 3.01 means the investor is paying $3.01 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyclopharm Ltd:

  • The EOD is 4.703. Based on the equity, the company is fair priced.
  • The MRQ is 3.007. Based on the equity, the company is fair priced.
  • The TTM is 3.007. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.703MRQ3.007+1.696
MRQ3.007TTM3.0070.000
TTM3.007YOY3.576-0.569
TTM3.0075Y6.234-3.227
5Y6.23410Y5.374+0.860
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD4.7032.098+2.605
MRQ3.0072.381+0.626
TTM3.0072.570+0.437
YOY3.5763.322+0.254
5Y6.2343.911+2.323
10Y5.3744.258+1.116
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cyclopharm Ltd.

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cyclopharm Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.070-0.0700%0.276-125%0.041-269%0.026-366%
Book Value Per Share--0.3890.3890%0.459-15%0.292+33%0.207+88%
Current Ratio--4.6464.6460%5.831-20%4.377+6%3.648+27%
Debt To Asset Ratio--0.2630.2630%0.227+15%0.290-9%0.290-10%
Debt To Equity Ratio--0.3560.3560%0.294+21%0.417-15%0.425-16%
Dividend Per Share--0.0090.0090%0.009+0%0.008+15%0.006+52%
Eps---0.070-0.0700%-0.054-24%-0.044-38%-0.024-66%
Free Cash Flow Per Share---0.077-0.0770%-0.030-61%-0.048-38%-0.019-75%
Free Cash Flow To Equity Per Share---0.085-0.0850%0.292-129%0.029-388%0.021-502%
Gross Profit Margin--1.4421.4420%1.203+20%5.463-74%3.174-55%
Intrinsic Value_10Y_max---0.493--------
Intrinsic Value_10Y_min---1.331--------
Intrinsic Value_1Y_max---0.026--------
Intrinsic Value_1Y_min---0.086--------
Intrinsic Value_3Y_max---0.095--------
Intrinsic Value_3Y_min---0.301--------
Intrinsic Value_5Y_max---0.186--------
Intrinsic Value_5Y_min---0.561--------
Market Cap171830236.320+36%109858675.680109858675.6800%153989938.560-29%142628485.776-23%98473748.820+12%
Net Profit Margin---0.285-0.2850%-0.2850%-0.238-16%-0.134-53%
Operating Margin---0.257-0.2570%-0.245-5%-0.211-18%-0.108-58%
Operating Ratio--1.3291.3290%1.393-5%1.390-4%1.177+13%
Pb Ratio4.703+36%3.0073.0070%3.576-16%6.234-52%5.374-44%
Pe Ratio-25.990-56%-16.616-16.6160%-30.553+84%-610.073+3572%-299.967+1705%
Price Per Share1.830+36%1.1701.1700%1.640-29%1.519-23%1.049+12%
Price To Free Cash Flow Ratio-23.771-56%-15.198-15.1980%-55.185+263%-52.790+247%28.343-154%
Price To Total Gains Ratio-30.420-56%-19.449-19.4490%5.739-439%41.333-147%-76.544+294%
Quick Ratio--3.5293.5290%5.027-30%3.508+1%2.891+22%
Return On Assets---0.133-0.1330%-0.090-32%-0.106-21%-0.069-48%
Return On Equity---0.181-0.1810%-0.117-35%-0.156-14%-0.138-24%
Total Gains Per Share---0.060-0.0600%0.286-121%0.049-222%0.032-286%
Usd Book Value--23894942.94023894942.9400%28166298.036-15%17911766.126+33%12691537.015+88%
Usd Book Value Change Per Share---0.045-0.0450%0.181-125%0.027-269%0.017-366%
Usd Book Value Per Share--0.2540.2540%0.300-15%0.191+33%0.135+88%
Usd Dividend Per Share--0.0060.0060%0.006+0%0.005+15%0.004+52%
Usd Eps---0.046-0.0460%-0.035-24%-0.029-38%-0.016-66%
Usd Free Cash Flow---4727392.566-4727392.5660%-1824943.836-61%-2925688.097-38%-1163469.139-75%
Usd Free Cash Flow Per Share---0.050-0.0500%-0.019-61%-0.031-38%-0.012-75%
Usd Free Cash Flow To Equity Per Share---0.055-0.0550%0.191-129%0.019-388%0.014-502%
Usd Market Cap112376974.553+36%71847573.89571847573.8950%100709419.818-29%93279029.698-23%64401831.728+12%
Usd Price Per Share1.197+36%0.7650.7650%1.073-29%0.993-23%0.686+12%
Usd Profit---4323930.810-4323930.8100%-3296268.564-24%-2700132.260-38%-1442588.164-67%
Usd Revenue--15185093.23815185093.2380%11578791.396+31%10867197.671+40%9624804.204+58%
Usd Total Gains Per Share---0.039-0.0390%0.187-121%0.032-222%0.021-286%
 EOD+5 -3MRQTTM+0 -0YOY+7 -295Y+13 -2310Y+16 -20

4.2. Fundamental Score

Let's check the fundamental score of Cyclopharm Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-25.990
Price to Book Ratio (EOD)Between0-14.703
Net Profit Margin (MRQ)Greater than0-0.285
Operating Margin (MRQ)Greater than0-0.257
Quick Ratio (MRQ)Greater than13.529
Current Ratio (MRQ)Greater than14.646
Debt to Asset Ratio (MRQ)Less than10.263
Debt to Equity Ratio (MRQ)Less than10.356
Return on Equity (MRQ)Greater than0.15-0.181
Return on Assets (MRQ)Greater than0.05-0.133
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cyclopharm Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.205
Ma 20Greater thanMa 501.802
Ma 50Greater thanMa 1001.873
Ma 100Greater thanMa 2002.039
OpenGreater thanClose1.840
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets49,542
Total Liabilities13,006
Total Stockholder Equity36,537
 As reported
Total Liabilities 13,006
Total Stockholder Equity+ 36,537
Total Assets = 49,542

Assets

Total Assets49,542
Total Current Assets36,870
Long-term Assets12,672
Total Current Assets
Cash And Cash Equivalents 20,296
Net Receivables 7,706
Inventory 8,293
Other Current Assets 571
Total Current Assets  (as reported)36,870
Total Current Assets  (calculated)36,865
+/- 5
Long-term Assets
Property Plant Equipment 6,600
Goodwill 865
Intangible Assets 4,571
Other Assets 636
Long-term Assets  (as reported)12,672
Long-term Assets  (calculated)12,672
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities7,936
Long-term Liabilities5,070
Total Stockholder Equity36,537
Total Current Liabilities
Short-term Debt 210
Accounts payable 4,400
Other Current Liabilities 3,326
Total Current Liabilities  (as reported)7,936
Total Current Liabilities  (calculated)7,936
+/-0
Long-term Liabilities
Long term Debt Total 4,122
Other Liabilities 948
Deferred Long Term Liability 789
Long-term Liabilities  (as reported)5,070
Long-term Liabilities  (calculated)5,858
+/- 789
Total Stockholder Equity
Common Stock63,421
Retained Earnings -29,073
Accumulated Other Comprehensive Income 2,189
Total Stockholder Equity (as reported)36,537
Total Stockholder Equity (calculated)36,537
+/-0
Other
Capital Stock63,421
Cash and Short Term Investments 20,296
Common Stock Shares Outstanding 92,179
Liabilities and Stockholders Equity 49,542
Net Debt -15,965
Net Invested Capital 36,537
Net Tangible Assets 31,889
Net Working Capital 28,935
Property Plant and Equipment Gross 9,044
Short Long Term Debt Total 4,332



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-31
> Total Assets 
20,995
9,206
10,978
18,580
19,644
22,142
21,293
21,656
11,899
10,961
16,541
16,415
23,377
23,537
32,528
28,275
55,741
49,542
49,54255,74128,27532,52823,53723,37716,41516,54110,96111,89921,65621,29322,14219,64418,58010,9789,20620,995
   > Total Current Assets 
12,845
0
7,764
12,444
12,170
8,409
8,687
9,033
7,452
8,850
13,098
11,061
16,829
15,454
19,611
15,979
43,252
36,870
36,87043,25215,97919,61115,45416,82911,06113,0988,8507,4529,0338,6878,40912,17012,4447,764012,845
       Cash And Cash Equivalents 
8,657
1,403
1,205
4,206
4,612
1,542
2,044
2,347
1,221
3,268
6,445
4,591
8,690
5,855
12,660
1,874
29,249
20,296
20,29629,2491,87412,6605,8558,6904,5916,4453,2681,2212,3472,0441,5424,6124,2061,2051,4038,657
       Net Receivables 
2,488
3,593
3,979
4,727
4,281
4,295
4,139
3,784
3,629
3,269
4,421
3,738
5,338
6,247
3,980
8,837
8,041
7,706
7,7068,0418,8373,9806,2475,3383,7384,4213,2693,6293,7844,1394,2954,2814,7273,9793,5932,488
       Inventory 
1,546
2,013
2,348
2,855
3,243
2,547
2,487
2,885
2,581
2,285
2,209
2,633
2,677
2,772
2,495
4,736
5,511
8,293
8,2935,5114,7362,4952,7722,6772,6332,2092,2852,5812,8852,4872,5473,2432,8552,3482,0131,546
       Other Current Assets 
154
0
232
655
33
25
17
17
21
28
24
99
124
581
250
297
392
571
57139229725058112499242821171725336552320154
   > Long-term Assets 
8,150
0
3,214
6,136
7,475
13,732
12,606
12,623
4,448
2,111
3,443
5,354
6,548
8,082
12,918
12,296
12,489
12,672
12,67212,48912,29612,9188,0826,5485,3543,4432,1114,44812,62312,60613,7327,4756,1363,21408,150
       Property Plant Equipment 
973
847
973
5,417
7,365
10,060
9,717
9,527
742
729
632
2,341
2,682
2,468
6,279
5,815
6,246
6,600
6,6006,2465,8156,2792,4682,6822,3416327297429,5279,71710,0607,3655,417973847973
       Goodwill 
6,532
0
0
0
0
0
0
0
0
0
0
0
400
865
865
865
865
865
865865865865865400000000000006,532
       Intangible Assets 
195
459
1,910
103
110
2,621
2,808
3,096
3,527
707
1,312
1,717
2,367
3,705
4,280
4,427
4,557
4,571
4,5714,5574,4274,2803,7052,3671,7171,3127073,5273,0962,8082,6211101031,910459195
       Long-term Assets Other 
119
0
3
0
0
864
80
0
178
0
0
5,354
6,548
8,082
12,918
0
0
0
00012,9188,0826,5485,354001780808640030119
> Total Liabilities 
9,655
9,772
3,635
5,524
5,716
8,376
6,688
6,048
5,349
3,205
3,439
3,953
6,128
6,521
9,324
11,159
12,673
13,006
13,00612,67311,1599,3246,5216,1283,9533,4393,2055,3496,0486,6888,3765,7165,5243,6359,7729,655
   > Total Current Liabilities 
2,150
4,421
1,585
1,938
4,330
7,979
6,575
5,928
5,210
2,920
3,221
3,896
5,211
5,219
3,480
5,684
7,418
7,936
7,9367,4185,6843,4805,2195,2113,8963,2212,9205,2105,9286,5757,9794,3301,9381,5854,4212,150
       Short-term Debt 
0
0
0
0
1,757
6,078
4,803
3,604
2,417
46
46
0
88
121
173
149
178
210
21017814917312188046462,4173,6044,8036,0781,7570000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
2,417
46
46
0
67
59
0
0
0
0
00005967046462,41700000000
       Accounts payable 
0
1,155
943
915
1,414
689
639
1,143
1,126
902
1,049
1,797
1,562
2,366
1,408
3,297
2,174
4,400
4,4002,1743,2971,4082,3661,5621,7971,0499021,1261,1436396891,4149159431,1550
       Other Current Liabilities 
388
817
642
1,022
1,158
1,212
1,133
1,181
1,667
1,972
2,126
2,099
3,562
2,733
1,900
2,239
5,066
3,326
3,3265,0662,2391,9002,7333,5622,0992,1261,9721,6671,1811,1331,2121,1581,022642817388
   > Long-term Liabilities 
7,505
0
2,050
3,586
1,386
397
113
120
138
285
218
57
916
1,302
5,844
5,475
5,255
5,070
5,0705,2555,4755,8441,302916572182851381201133971,3863,5862,05007,505
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
152
0
87
0
4,750
4,558
4,332
4,122
4,1224,3324,5584,75008701520000000000
       Other Liabilities 
0
121
24
31
43
28
64
84
121
72
66
397
829
1,302
1,094
917
923
948
9489239171,0941,30282939766721218464284331241210
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
39
42
175
249
427
723
789
789
789
789
789789789789723427249175423900000000
> Total Stockholder Equity
11,340
0
7,342
13,056
13,929
13,766
14,605
15,608
6,550
7,756
13,102
12,462
17,249
17,016
23,204
17,116
43,068
36,537
36,53743,06817,11623,20417,01617,24912,46213,1027,7566,55015,60814,60513,76613,92913,0567,342011,340
   Common Stock
14,699
6,515
7,841
10,867
11,089
11,089
13,065
14,967
14,963
14,963
14,963
14,963
21,552
21,905
31,576
31,632
62,974
63,421
63,42162,97431,63231,57621,90521,55214,96314,96314,96314,96314,96713,06511,08911,08910,8677,8416,51514,699
   Retained Earnings 
-2,872
0
-241
1,515
3,456
3,906
2,950
1,906
-7,734
-7,049
-2,534
-2,199
-4,324
-5,011
-8,861
-15,657
-21,579
-29,073
-29,073-21,579-15,657-8,861-5,011-4,324-2,199-2,534-7,049-7,7341,9062,9503,9063,4561,515-2410-2,872
   Accumulated Other Comprehensive Income 
-487
0
-258
673
-616
-1,229
-1,410
-1,264
-679
-158
674
-302
22
122
489
1,141
1,672
2,189
2,1891,6721,14148912222-302674-158-679-1,264-1,410-1,229-616673-2580-487
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.